Phase I Study of MLN8237 in Combination With Cetuximab and Definitive Radiation in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
Latest Information Update: 02 Apr 2023
At a glance
- Drugs Alisertib (Primary) ; Cetuximab (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Nasopharyngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 28 Aug 2018 Status changed from active, no longer recruiting to completed.
- 18 Jul 2016 Status changed from completed to active, no longer recruiting.
- 06 Mar 2012 New trial record